Stay ahead of IBD
It’s time to flip the script and to be proactive.
In this short video series, we’ll explore three powerful strategies designed to help you gain early and effective control over IBD:
timely monitoring, top-down treatment, and aiming for ambitious therapeutic goals.1-5
Ready to see what proactive care really looks like? Press play.
Start at the TOP
Prof. Kobi Ollech
Aiming For Mucosal Healing
Rinvoq 15/30 mg and Skyrizi 360 mg have demonstrated mucosal healing* rates of up to 31% in patients with moderate to severe Crohn's disease.
Rinvoq 15/30 mg and Skyrizi 180/360 mg has demonstrated mucosal healing* rates of approximately 60% in patients with moderate to severe Ulcerative Colitis, alongside a well-known and consistent safety profile across several indications and thousands of patient years.6-7
So, What are you waiting for?
Swipe to see more from RINVOQ and SKYRIZI
Rinvoq – Crohn’s Disease (U-ENDURE)
Exposure-adjusted event rates for treatment-emergent adverse events were numerically lower with upadacitinib 15 mg and 30 mg compared with placebo, except for COVID-19 and adverse events leading to early discontinuation of treatment. No deaths, active tuberculosis, lymphoma, nonmelanoma skin cancer, adjudicated major cardiovascular events, or venous thromboembolic events were reported in any treatment group. Herpes zoster infections occurred more frequently in upadacitinib-treated patients but were all nonserious and typically limited to a single dermatome. Overall, the safety profile f upadacitinib in patients with Crohn’s disease remained consistent, with no new safety signals identified
1. Loftus et al. NEJM 2023
Skyrizi – Crohn’s Disease (FORTIFY)
Exposure-adjusted event rates of serious adverse events, adverse events leading to study drug discontinuation, and serious infections were comparable across risankizumab and placebo groups. No new or unexpected safety findngs were observed, and the incidence and type of reported events were consistent with prior experience in clinical studies of risankizumab. Overall, continued subcutaneous maintenance treatment with risankizumab in patients with Crohn’s disease maintained a favorable safety profie.
1. Ferrante et al. Lancet 2022
Rinvoq – Ulcerative Colitis (U-ACHIEVE)
The safety profile bserved was consistent with previous analyses and other approved indications. No new safety risks were identifid during extended exposure, and adverse events were in line with the known safety characteristics of upadacitinib. Overall, upadacitinib maintenance therapy through 52 weeks demonstrated a predictable and manageable safety profile inulcerative colitis.
1. Danese et al. Lancet 2022
Skyrizi – Ulcerative Colitis (COMMAND)
The rate of overall adverse events was similar between risankizumab and placebogroups, and no new safety signals were identifid over 52 weeks of therapy. The nature and frequency of adverse events observed were consistent with previous risankizumab studies in Crohn’s disease and other indications. Overall, risankizumab demonstrated a stable and reassuring long-term safety profile n patients with ulcerative colitis.
1. Louis et al JAMA 2024
Previous
Next
For more information
IL-SKZG-260001 Jan2026
Indications:6-7
SKYRIZI
Skyrizi 360mg and 600mg are indicated for the treatment of patients 16 years and older with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable.
Skyrizi 180mg, 360mg and 600mg are indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
RINVOQ
RINVOQ 15 MG/RINVOQ 30 MG/RINVOQ 45 MG is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
RINVOQ 15 MG/RINVOQ 30 MG/RINVOQ 45 MG is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent
1.Noor N, et al. Lancet Gastroenterol Hepatol. 2024. S2468–53(24)00034–7. 2. Colombel JF, et al. Lancet. 2017;390:2779–89. 3. Colombel JF, et al. Gastroenterology. 2017;152:351–61; 4.Pariente B, et al. Inflamm Bowel Dis. 2011;17:1415–22. 5. Khanna R, et al. Clin Gastroenterol Hepatol. 2022;20:727–36.e2. 6. Skyrizi prescribing information 7. Rinvoq prescribing information
*For Crohn's disease studies, mucosal healing was defined as SES-CD ulcerated surface subscore of 0 in patients with SES-CD ulcerated surface subscore ≥ 1 at baseline. For Ulcerative colitis studies, mucosal healing was defined as ESS ≤ 1 without friability.